STOCK TITAN

ICU Medical (ICUI) director reports RSU vesting and new equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ICU Medical director Kolleen T. Kennedy reported compensation-related equity activity in the company’s stock. On May 13, 2026, 1,254 Restricted Stock Units vested and were settled into an equal number of ICU Medical common shares, bringing her direct holdings to 4,539 shares.

On the same date, Kennedy also received a new grant of 1,475 Restricted Stock Units. According to the disclosure, these units have no purchase or exercise price and will vest on the anniversary of the grant date or at the following annual stockholder meeting, whichever occurs first.

Positive

  • None.

Negative

  • None.
Insider KENNEDY KOLLEEN T
Role null
Type Security Shares Price Value
Exercise Common Stock 1,254 $0.00 --
Grant/Award Common Stock 1,475 $0.00 --
Exercise Common Stock 1,254 $0.00 --
Holdings After Transaction: Common Stock — 0 shares (Direct, null)
Footnotes (1)
  1. These securities are Restricted Stock Units. There is neither a purchase price nor an exercise price for Restricted Stock Units. These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.
RSUs vested into shares 1,254 shares Restricted Stock Units converted to ICU Medical common stock on May 13, 2026
New RSU grant 1,475 RSUs Equity award to director on May 13, 2026
Shares held after transactions 4,539 shares Direct ICU Medical common stock holdings after Form 4 transactions
RSU purchase/exercise price $0.00 No purchase or exercise price for Restricted Stock Units
RSU vesting date condition Anniversary or next meeting Vests on grant anniversary or following annual stockholder meeting, whichever occurs first
Restricted Stock Units financial
"These securities are Restricted Stock Units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KENNEDY KOLLEEN T

(Last)(First)(Middle)
951 CALLE AMANECER

(Street)
SAN CLEMENTE CALIFORNIA 92673

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)05/13/2026M1,254A$0(2)4,539D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock(1)$0(2)05/13/2026M1,25405/13/2026(3)05/13/2026Common Stock1,254$00D
Common Stock(1)$0(2)05/13/2026A1,47505/13/2027(3)05/13/2027Common Stock1,475$01,475D
Explanation of Responses:
1. These securities are Restricted Stock Units.
2. There is neither a purchase price nor an exercise price for Restricted Stock Units.
3. These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.
Paula Darbyshire, Attorney-in-fact For: Kolleen T. Kennedy05/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ICU Medical (ICUI) disclose for Kolleen T. Kennedy?

ICU Medical disclosed that director Kolleen T. Kennedy had 1,254 Restricted Stock Units vest into common shares and received a new grant of 1,475 Restricted Stock Units, all dated May 13, 2026, as part of her equity compensation.

How many ICU Medical (ICUI) shares does Kolleen T. Kennedy hold after the latest Form 4?

After the reported transactions, Kolleen T. Kennedy directly holds 4,539 shares of ICU Medical common stock. This reflects the settlement of 1,254 vested Restricted Stock Units into common shares on May 13, 2026, as shown in the Form 4 filing data.

What Restricted Stock Unit grant did ICU Medical (ICUI) report for Kolleen T. Kennedy?

ICU Medical reported a grant of 1,475 Restricted Stock Units to director Kolleen T. Kennedy on May 13, 2026. These RSUs have no purchase or exercise price and are scheduled to vest on the grant’s anniversary or the next annual stockholder meeting, whichever occurs first.

Do Kolleen T. Kennedy’s ICU Medical (ICUI) Restricted Stock Units have an exercise price?

The Restricted Stock Units reported for Kolleen T. Kennedy have no purchase or exercise price. The filing specifies that RSUs do not require payment to convert into common shares, reflecting standard equity compensation terms rather than open-market stock purchases.

When will Kolleen T. Kennedy’s new ICU Medical (ICUI) RSU award vest?

The 1,475 Restricted Stock Units granted to Kolleen T. Kennedy will vest on the anniversary of the May 13, 2026 grant date or at the following annual stockholder meeting, whichever occurs first, according to the vesting terms disclosed in the Form 4 footnotes.